lintuzumab
(lin-TOO-zoo-mab)
A substance being studied in the treatment of myelodysplastic syndromes and some types of leukemia. It binds to CD33, a protein on the surface of certain normal blood stem cells and some abnormal blood cells. It causes the immune system to kill these cells. Lintuzumab is a type of monoclonal antibody. Also called MoAb HuM195 and monoclonal antibody HuM195.